The Trump administration has signed a $354 million contract with a Virginia-based company that will lead efforts to manufacture key medicines and drug ingredients for use in the fight against COVID-19.
Phlow Corp. is heading a team that will make active pharmaceutical ingredients and the chemical compounds for those ingredients, as well as generic drugs that are in short supply because of surges in hospitalized patients due to the CCP (Chinese Communist Party) virus pandemic.
